The Asphyxia market report also offers comprehensive insights into the Asphyxia market size, share, Asphyxia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Asphyxia market size growth forward.
Some of the key highlights from the Asphyxia Market Insights Report:
Several key pharmaceutical companies, including Pharmazz, Inc., ReAlta Life Sciences, Acer Therapeutics, and others, are developing novel products to improve the Asphyxia treatment outlook.
In December 2024, the U.S. Food and Drug Administration approved Zepbound for treating moderate to severe OSA in adults with obesity. Zepbound functions by activating receptors of intestinal hormones to reduce appetite and food intake, leading to weight loss and improvement in OSA symptoms. Clinical trials demonstrated a significant reduction in apnea and hypopnea events among participants treated with Zepbound compared to placebo.
A Phase I clinical study conducted at the Montreal Children’s Hospital explored the use of sildenafil, commonly known as Viagra, to treat newborns suffering from neonatal encephalopathy due to oxygen deprivation during birth. The study found that sildenafil administration is feasible and safe, showing encouraging signs of efficacy in repairing brain injury caused by birth asphyxia. Further research is ongoing to confirm these findings and establish optimal dosing.
Recent developments in clinical trials for asphyxia have demonstrated significant progress in addressing this critical condition. On August 2, 2023, ReAlta Life Sciences launched a Phase II trial to assess the safety, tolerability, pharmacokinetics, and preliminary effectiveness of RLS-0071 in newborns with hypoxic-ischemic encephalopathy (HIE), also known as birth asphyxia. This randomized, double-blind, placebo-controlled study follows a two-stage, multiple-ascending dose design to explore potential treatments for affected newborns.
Additionally, a randomized clinical trial conducted by the HEAL Consortium and published in the *New England Journal of Medicine* on January 12, 2022, examined the use of erythropoietin in treating HIE. The study aimed to improve outcomes for infants with birth asphyxia, providing crucial insights for future therapeutic approaches. These advancements highlight ongoing efforts to enhance the understanding and management of asphyxia, ultimately working toward better patient outcomes.
As per DelveInsight analysis, the Asphyxia market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Asphyxia Market Landscape
Asphyxia Overview
Asphyxia is a condition caused by insufficient oxygen supply, which can lead to organ failure and life-threatening complications. It can result from airway obstruction, drowning, suffocation, or exposure to toxic gases, triggering symptoms such as rapid heart rate, confusion, and loss of consciousness.
There are three main types of asphyxia:
– Mechanical Asphyxia – Caused by airway obstruction or external pressure on the chest.
– Chemical Asphyxia – Results from inhaling toxic substances like carbon monoxide or cyanide, which prevent oxygen utilization.
– Environmental Asphyxia – Occurs in low-oxygen environments, such as confined spaces or high altitudes.
Common symptoms include breathing difficulties, cyanosis (bluish skin), and, in severe cases, unconsciousness or death. Immediate treatment is essential and may involve clearing the airway, providing oxygen, or performing CPR. Early intervention and awareness are crucial in preventing severe outcomes.
Do you know the treatment paradigms for different countries? Download our Asphyxia Market Sample Report
Asphyxia Epidemiology Insights
Asphyxia, a condition caused by insufficient oxygen supply, affects individuals across various age groups and settings. It is a significant global health concern, particularly in newborns and adults exposed to environmental or occupational hazards.
Birth asphyxia affects approximately 2 to 3 per 1,000 live births in high-income countries but is significantly higher in low- and middle-income regions, where it contributes to one-quarter of all neonatal deaths.
Asphyxia Epidemiology Segmentation
DelveInsight’s Asphyxia market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Asphyxia historical patient pools and forecasted Asphyxia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Asphyxia Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Asphyxia Prevalence
Age-Specific Asphyxia Prevalence
Gender-Specific Asphyxia Prevalence
Diagnosed and Treatable Cases of Asphyxia
Visit for more @ Asphyxia Epidemiological Insights
Asphyxia Market Outlook
The market for asphyxia-related treatments, particularly focusing on neonatal asphyxia or asphyxia neonatorum, is projected to experience significant growth in the coming years.
The asphyxia market growth is largely attributed to advancements in neuroprotective therapies, including the development of novel therapeutic agents such as neuroprotective drugs, surfactants, and anti-inflammatory agents. These innovations aim to more effectively address the pathophysiology of neonatal asphyxia, targeting critical issues like neuroinflammation and oxygen deprivation-induced brain injury.
Asphyxia Key Companies
Pharmazz, Inc., ReAlta Life Sciences, Acer Therapeutics, and others
For more information, visit Asphyxia Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Asphyxia Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Asphyxia, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Asphyxia epidemiology in the 7MM
Asphyxia marketed and emerging therapies
Asphyxia companies
Asphyxia market drivers and barriers
Table of Contents:
1 Asphyxia Market Key Comprehensive Insights
2 Asphyxia Market Report Introduction
3 Competitive Intelligence Analysis for Asphyxia
4 Asphyxia Market Analysis Overview at a Glance
5 Executive Summary of Asphyxia
6 Asphyxia Epidemiology and Market Methodology
7 Asphyxia Epidemiology and Patient Population
8 Asphyxia Patient Journey
9 Asphyxia Treatment Algorithm, Asphyxia Current Treatment, and Medical Practices
10 Key Endpoints in Asphyxia Clinical Trials
11 Asphyxia Marketed Therapies
12 Asphyxia Emerging Therapies
13 Asphyxia: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Asphyxia
16 Asphyxia Market Key Opinion Leaders Reviews
18 Asphyxia Market Drivers
19 Asphyxia Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Asphyxia Epidemiology 2032
DelveInsight’s “Asphyxia – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Asphyxia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Asphyxia Pipeline 2024
“Asphyxia Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Asphyxia market. A detailed picture of the Asphyxia pipeline landscape is provided, which includes the disease overview and Asphyxia treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
